Interventional Oncology Market Report 2026

Interventional Oncology Market Overview

• Interventional Oncology market size has reached to $2.72 billion in 2025 • Expected to grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.7% • Growth Driver: Increasing Prevalence Of Cancer Fueling The Growth Of The Market Due To Rising Lifestyle-Related Risk Factors And Growing Cancer Cases • Market Trend: Innovative Catheter-Based Therapy Enhances Precision In Liver Cancer Treatment • North America was the largest region in 2025 and Asia-Pacific is the fastest growing region.

What Is Covered Under Interventional Oncology Market?

Interventional oncology is a medical specialty focused on minimally invasive, image-guided procedures to diagnose and treat cancer. Its primary purpose is to provide effective cancer treatment options with reduced recovery times and fewer side effects compared to traditional surgery. The main types of interventional oncology are radiation therapy devices, ablation devices, and embolization devices. Radiation therapy devices are specialized medical equipment designed to deliver controlled doses of ionizing radiation to targeted areas in the body to treat cancer and other diseases by destroying or damaging abnormal cells while minimizing harm to surrounding healthy tissue. These devices utilize technologies such as ultrasound, computed tomography guidance, and magnetic resonance guidance, and the procedures performed include tumor ablation, tumor biopsy, vascular interventions, and palliative care. These treatments are applied to various cancers, including liver cancer, lung cancer, kidney cancer, pancreatic cancer, and prostate cancer, and cater to various end-users such as hospitals, ambulatory surgical centers, specialty clinics, and research and academic institutions.

What Is The Interventional Oncology Market Growth Forecast?

The interventional oncology market size is expected to see strong growth in the next few years. It will grow to $4.14 billion in 2030 at a compound annual growth rate (CAGR) of 8.7%. The growth in the forecast period can be attributed to increasing adoption of AI-assisted imaging guidance, rising demand for outpatient cancer treatments, expansion of personalized oncology approaches, growing investments in advanced ablation technologies, increasing focus on reduced patient recovery times. Major trends in the forecast period include increasing adoption of image-guided cancer therapies, rising use of minimally invasive ablation procedures, growing integration of advanced imaging modalities, expansion of targeted tumor treatment techniques, enhanced focus on precision oncology.

Global Interventional Oncology Market Segmentation

1) By Type: Radiation Therapy Devices, Ablation Devices, Embolization Devices 2) By Technology Type: Ultrasound, Computed Tomography Guided, Magnetic Resonance-Guided 3) By Procedure: Tumor Ablation, Tumor Biopsy, Vascular Interventions, Palliative Care 4) By Application Areas: Liver Cancer, Lung Cancer, Kidney Cancer, Pancreatic Cancer, Prostate Cancer 5) By End-Users: Hospitals, Ambulatory Surgical Centers, Specialty Clinics, Research And Academic Institutions Subsegments: 1) By Radiation Therapy Devices: Linear Accelerators, Proton Therapy Systems, Brachytherapy Devices 2) By Ablation Devices: Radiofrequency Ablation Devices, Microwave Ablation Devices, Cryoablation Devices, Irreversible Electroporation Systems 3) By Embolization Devices: Microspheres, Coil Embolization Devices, Liquid Embolic Agents, Embolic Protection Devices

What Is The Driver Of The Interventional Oncology Market?

The increasing prevalence of cancer is expected to propel the growth of the interventional oncology market going forward. Prevalence of cancer refers to the total number of people, both newly diagnosed and previously diagnosed, who are alive with a history of cancer at a specific point in time. The prevalence of cancer is increasing due to lifestyle-related risks such as poor diet, smoking, alcohol consumption, and exposure to environmental pollutants, elevating the risk of developing various cancers. Interventional oncology aids in cancer treatment by providing minimally invasive, targeted therapies that focus directly on tumors. It improves patient outcomes by reducing damage to healthy tissue and offers faster recovery times compared to traditional treatments. For instance, in February 2024, according to the World Health Organization, a Switzerland-based international organization specializing in global health policy and public health initiatives, over 35 million new cancer cases are predicted in 2050, a 77% increase from the estimated 20 million cases in 2022. Therefore, the increasing prevalence of cancer is driving the growth of the interventional oncology industry.

Key Players In The Global Interventional Oncology Market

Major companies operating in the interventional oncology market are Johnson & Johnson, Siemens Healthineers AG, Stryker Corporation, GE HealthCare Technologies Inc., Boston Scientific Corporation, Terumo Corporation, Hologic Inc., Teleflex Incorporated, Lantheus Holdings Inc., Penumbra Inc., Merit Medical Systems Inc., Guerbet SA, Asahi Intecc Co. Ltd., AngioDynamics Inc., Sirtex Medical Limited, Delcath Systems Inc., ABK Biomedical Inc., Profound Medical Inc., IceCure Medical Ltd., Medtronic plc, Koninklijke Philips NV, Cook Medical Incorporated

Global Interventional Oncology Market Trends and Insights

Major companies operating in the interventional oncology market are focusing on developing advanced products, such as microcatheter-based embolization systems, to deliver precise, targeted cancer therapy while minimizing damage to surrounding healthy tissue. Microcatheter-based embolization systems refer to medical devices that use tiny, flexible catheters to deliver embolic agents precisely into blood vessels to block or reduce blood flow, typically for treating tumors, vascular malformations, or bleeding. For instance, in March 2025, Terumo Corporation, a Japan-based medical device company, launched the Occlusafe balloon occlusion catheter based on its advanced Balloon-TACE (B-TACE) therapy for the treatment of liver cancer, particularly hepatocellular carcinoma (HCC). This specialized microcatheter leverages the pressure gradient effect to redirect blood flow and access the microcirculation, enabling higher concentrations of therapeutic agents at the tumor site while minimizing off-target embolization. This targeted approach aims to improve clinical outcomes in difficult-to-treat liver cancer cases by enhancing drug delivery precision and offering improved visualization during procedures.

What Are Latest Mergers And Acquisitions In The Interventional Oncology Market?

In June 2025, Boston Scientific Corporation, a US-based healthcare technology company, acquired Intera Oncology Inc. for an undisclosed amount. With this acquisition, Boston Scientific aims to expand its interventional oncology offerings and strengthen its liver-directed therapy portfolio by integrating Intera’s hepatic artery infusion capabilities into its Peripheral Interventions division. Intera Oncology Inc. is a US-based medical device company that specialises in hepatic artery infusion therapy and commercialises the FDA-approved Intera 3000 Hepatic Artery Infusion Pump and floxuridine chemotherapy for treating liver-dominant metastases.

Regional Outlook

North America was the largest region in the interventional oncology market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in this market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in this market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

What Defines the Interventional Oncology Market?

The interventional oncology market consists of revenues earned by entities by providing services such as image-guided tumor ablation, biopsy and diagnostic imaging, pain palliation procedures, and thermal ablation planning and follow-up. The market value includes the value of related goods sold by the service provider or included within the service offering. The interventional oncology market also includes sales of image-guided navigation systems, catheters and guidewires, radiation delivery systems, and biopsy needles and systems. Values in this market are ‘factory gate’ values; that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

How is Market Value Defined and Measured?

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified). The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

What Key Data and Analysis Are Included in the Interventional Oncology Market Report 2026?

The interventional oncology market research report is one of a series of new reports from The Business Research Company that provides market statistics, including industry global market size, regional shares, competitors with the market share, detailed market segments, market trends and opportunities, and any further data you may need to thrive in the interventional oncology industry. The market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future state of the industry.